MSD issued a statement: MSD has begun negotiations with Sinopharm Group on licensing the production technology of monolavir, so that the Sinopharm Group can produce and supply this drug in China in the future. (MSD China(WeChat account)
默沙东：已与国药集团展开莫诺拉韦的生产技术许可谈判
MSD: Monolavir production technology license negotiations have begun with Sinopharm Group
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.